Pfizer Inc (NYSE: PFE) on Tuesday, plunged -3.49% from the previous trading day, before settling in for the closing price of $22.63. Within the past 52 weeks, PFE’s price has moved between $21.75 and $31.54.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 17.19% over the past five years. The company achieved an average annual earnings per share of -5.04%. With a float of $5.67 billion, this company’s outstanding shares have now reached $5.67 billion.
Let’s look at the performance matrix of the company that is accounted for 81000 employees. In terms of profitability, gross margin is 65.57%, operating margin of 23.43%, and the pretax margin is 12.61%.
Pfizer Inc (PFE) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Pfizer Inc is 0.04%, while institutional ownership is 67.13%. The most recent insider transaction that took place on Mar 04 ’25, was worth 64,825. In this transaction SVP & Controller of this company sold 2,500 shares at a rate of $25.93, taking the stock ownership to the 11,850 shares. Before that another transaction happened on Feb 13 ’25, when Company’s Director bought 19,457 for $25.65, making the entire transaction worth $499,072. This insider now owns 27,707 shares in total.
Pfizer Inc (PFE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -5.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.38% during the next five years compared to -13.25% drop over the previous five years of trading.
Pfizer Inc (NYSE: PFE) Trading Performance Indicators
Pfizer Inc (PFE) is currently performing well based on its current performance indicators. A quick ratio of 0.92 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.95. Likewise, its price to free cash flow for the trailing twelve months is 12.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.41, a number that is poised to hit 0.70 in the next quarter and is forecasted to reach 3.02 in one year’s time.
Technical Analysis of Pfizer Inc (PFE)
Pfizer Inc (NYSE: PFE) saw its 5-day average volume 66.8 million, a positive change from its year-to-date volume of 47.08 million. As of the previous 9 days, the stock’s Stochastic %D was 11.07%. Additionally, its Average True Range was 0.72.
During the past 100 days, Pfizer Inc’s (PFE) raw stochastic average was set at 6.53%, which indicates a significant decrease from 7.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.16% in the past 14 days, which was higher than the 24.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.72, while its 200-day Moving Average is $27.41. Nevertheless, the first resistance level for the watch stands at $22.74 in the near term. At $23.64, the stock is likely to face the second major resistance level. The third major resistance level sits at $24.29. If the price goes on to break the first support level at $21.19, it is likely to go to the next support level at $20.54. The third support level lies at $19.64 if the price breaches the second support level.
Pfizer Inc (NYSE: PFE) Key Stats
Market capitalization of the company is 123.86 billion based on 5,671,455K outstanding shares. Right now, sales total 63,627 M and income totals 8,031 M. The company made 17,763 M in profit during its latest quarter, and 410,000 K in sales during its previous quarter.
